Human Papillomavirus (HPV) Infection

1. Clinical Overview

Summary

Human Papillomavirus (HPV) is a double-stranded DNA virus of the Papillomaviridae family, representing the most common sexually transmitted infection (STI) worldwide. Over 200 HPV genotypes have been identified, with approximately 40 types infecting the anogenital tract. [1] The virus exhibits tropism for squamous epithelium, infecting basal keratinocytes through microabrasions during sexual contact. [2]

HPV infections are categorised into high-risk (oncogenic) and low-risk (non-oncogenic) types based on their oncogenic potential. High-risk types, particularly HPV 16 and 18, are responsible for approximately 70% of cervical cancers worldwide and contribute significantly to other anogenital and oropharyngeal malignancies. [3,4] Low-risk types, predominantly HPV 6 and 11, cause ~90% of genital warts (condylomata acuminata) but do not cause cancer. [5]

The natural history of HPV infection is characterised by transient infection in most cases, with ~90% of infections clearing spontaneously within 1-2 years through cell-mediated immunity. [6] However, persistent infection with high-risk HPV is the critical risk factor for progression to Cervical Intraepithelial Neoplasia (CIN) and invasive cervical cancer over decades. [7]

Prevention through HPV vaccination has revolutionised public health, with nonavalent vaccines (Gardasil-9) providing protection against 9 HPV types and preventing an estimated 90% of cervical cancers. [8] Cervical screening programmes using HPV primary testing have shifted from cytology-based to molecular detection, enabling earlier identification of high-risk infections. [9]

Clinical Pearls

"16 and 18 = Cancer Risk": HPV 16 and 18 cause ~70% of cervical cancers. HPV 16 alone accounts for 50-55% of cases and is the dominant type in oropharyngeal cancer. [3,10]

"6 and 11 = Warts, Not Cancer": HPV 6 and 11 cause ~90% of genital warts but have no oncogenic potential. Patients can be reassured. [5]

"Vaccine Prevents Cancer": HPV vaccination is the first vaccine to prevent cancer. Efficacy approaches 100% in vaccine-naive populations for targeted types. [8]

"Most Infections Clear Spontaneously": ~90% of HPV infections clear within 2 years. Persistence beyond 12-24 months indicates increased cancer risk. [6]

"Screening Detects Pre-Cancer, Not Infection": The goal of cervical screening is to detect CIN2/3, not merely HPV infection. HPV positivity requires cytology triage. [9]

"Immunosuppression = Persistence": HIV-positive patients have higher HPV persistence, CIN progression, and cervical cancer risk. Screen more frequently. [11]

---

2. Epidemiology

Global Burden

Demographics

Transmission Routes

HPV Type Distribution

---

3. Aetiology and Pathophysiology

Viral Structure and Genome

HPV is a non-enveloped, double-stranded DNA virus with a circular genome of ~8,000 base pairs. [1] The genome encodes:

• Early Proteins (E1-E7): Involved in viral replication, transcription, and oncogenesis.
• Late Proteins (L1, L2): Form the viral capsid. L1 is the target for vaccine development.

High-risk HPV types encode E6 and E7 oncoproteins, which are critical for malignant transformation. [18]

Exam Detail: ### Molecular Pathogenesis of HPV-Induced Carcinogenesis

1. Viral Entry and Infection

• HPV infects basal keratinocytes through microabrasions in the epithelium.
• The virus remains episomal (extrachromosomal) initially, with low copy numbers per cell.
• Viral replication is linked to keratinocyte differentiation: early genes expressed in basal layers, late genes in superficial layers. [2]

2. E6 and E7 Oncoproteins

E6 Oncoprotein:

• Binds and degrades p53 via ubiquitin-proteasome pathway.
• p53 is a tumour suppressor that induces apoptosis and cell cycle arrest in response to DNA damage.
• Loss of p53 function → loss of apoptosis, genomic instability, and accumulation of mutations. [18]

E7 Oncoprotein:

• Binds and inactivates Retinoblastoma (Rb) protein.
• Rb normally inhibits E2F transcription factors, preventing S-phase entry.
• E7-Rb binding → release of E2F → uncontrolled cell cycle progression (G1 to S phase). [18]

3. Viral Integration

• In persistent high-risk HPV infections, the viral genome may integrate into the host chromosome.
• Integration disrupts the E2 gene, which normally represses E6/E7 expression.
• Result: Constitutive overexpression of E6 and E7 → malignant transformation. [19]

4. Progression to Cancer

The progression from HPV infection to cancer occurs over 10-20 years and involves:

HPV Infection
      ↓
Persistent Infection (12-24+ months)
      ↓
CIN 1 (Low-grade dysplasia)
      ↓
CIN 2/3 (High-grade dysplasia)
      ↓
Invasive Cervical Cancer

• CIN 1: Often regresses (~60% regress, ~10% progress to CIN 3). [7]
• CIN 2/3: High risk of progression if untreated (~30-50% progress to invasive cancer over 10-30 years). [7]

Risk Factors for Persistence and Progression

Immune Response to HPV

---

4. Clinical Presentation

4.1 Asymptomatic Infection

• Most common presentation: 70-90% of HPV infections are subclinical.
• Detected incidentally through cervical screening (HPV-positive) or partner notification.

4.2 Genital Warts (Condylomata Acuminata)

Clinical Pearl: Examination Tip: Apply 5% acetic acid (not routinely used in UK primary care but used in specialist settings) causes acetowhitening of subclinical lesions. However, specificity is low (false positives with inflammation).

4.3 Cervical Intraepithelial Neoplasia (CIN)

4.4 Cervical Cancer

4.5 Oropharyngeal Cancer

4.6 Other Anogenital Cancers

4.7 Laryngeal Papillomatosis

---

5. Differential Diagnosis

Genital Warts

Cervical Lesions

---

6. Investigations

6.1 Genital Warts

6.2 Cervical Screening

UK NHS Cervical Screening Programme (2024)

Exam Detail: #### HPV Primary Screening Pathway

Cervical Sample Collected
          ↓
    HPV Test
          ↓
    ┌─────────┴─────────┐
HPV Negative        HPV Positive
    ↓                   ↓
Routine Recall      Reflex Cytology
(3 or 5 years)          ↓
                  ┌─────────┴─────────┐
            Cytology Normal    Cytology Abnormal
                  ↓                   ↓
            Repeat HPV Test      Colposcopy Referral
            at 12 months
                  ↓
        ┌─────────┴─────────┐
  HPV Negative        HPV Positive
        ↓                   ↓
  Routine Recall       Colposcopy

6.3 Colposcopy

6.4 HPV Testing Methods

6.5 HIV Testing

• Recommended for all HPV-related diagnoses (genital warts, CIN, HPV-related cancers).
• HIV-positive patients: Increased HPV persistence, faster CIN progression, higher cancer risk. [11]

---

7. Classification and Staging

7.1 HPV Type Classification

7.2 CIN Grading (Histological)

7.3 Cervical Cancer Staging (FIGO)

---

8. Management

8.1 Genital Warts

Exam Detail: #### Treatment Algorithm

GENITAL WARTS CONFIRMED
          ↓
    Assess Extent, Location, Patient Preference
          ↓
    ┌──────────────┴──────────────┐
PATIENT-APPLIED           CLINICIAN-APPLIED
    ↓                           ↓
Podophyllotoxin          Cryotherapy (1st-line)
0.5% cream/solution      Liquid nitrogen
BD for 3 days,           Repeat q 1-2 weeks
4 days off.              Up to 6 cycles
Max 4 cycles                 ↓
    ↓                   Electrosurgery/Excision
Imiquimod 5%             (if refractory or large)
3x/week at night             ↓
Max 16 weeks            Trichloroacetic Acid
                        80-90% (specialist)
                             ↓
                        Laser Ablation
                        (specialist, extensive)

    ↓
FOLLOW-UP
- Review at 3 months
- Recurrence ~30%
- May need repeated treatment
- Partner notification
- Full STI screen
- Reassure: No cancer risk (HPV 6/11)

Treatment Options

Clinical Pearl: Pregnancy: Genital warts may proliferate in pregnancy due to immunomodulation. Safe treatments: Cryotherapy, TCA, surgical excision. Avoid: Podophyllotoxin, imiquimod (insufficient safety data).

Adjuncts and Follow-Up

• Partner Notification: Inform current sexual partners. Often asymptomatic in partners. Examination if symptomatic.
• STI Screen: Full screen for chlamydia, gonorrhoea, HIV, syphilis.
• Recurrence: Common (~30%). May require repeated treatment. Usually occurs within 3 months.
• Psychological Support: Address anxiety, stigma, psychosexual concerns.

8.2 Cervical Intraepithelial Neoplasia (CIN)

CIN 1 Management

• Conservative approach: ~60% regress spontaneously. [7]
• Action: Repeat HPV test and/or cytology at 12 months.
• If persistent CIN 1 at 24 months: Consider colposcopy +/- treatment.

CIN 2/3 Management

Exam Detail: #### Post-Treatment Follow-Up (Test of Cure)

• Test of Cure (ToC): HPV test at 6 months post-treatment. [20]
• If HPV-negative: Return to routine recall (may be annual for 3 years, then 3-yearly).
• If HPV-positive: Colposcopy +/- cytology.
• Surveillance: More frequent screening for 10 years (annual or 3-yearly depending on protocol).

Complications of LLETZ

8.3 Cervical Cancer Management

• Multidisciplinary Team (MDT) approach: Gynaecological oncologists, clinical oncologists, radiologists, pathologists, CNS.

8.4 HPV-Related Anal, Vulvar, Vaginal, Penile Cancers

• Similar principles: Surgical excision for early-stage disease.
• Chemoradiotherapy for locally advanced anal cancer (5-FU + mitomycin C or cisplatin + radiotherapy).
• Surveillance for high-risk groups (HIV-positive, MSM): Anal cytology and high-resolution anoscopy.

8.5 Oropharyngeal Cancer

• HPV-positive tumours: Better prognosis. May be candidates for de-escalation therapy (lower radiation doses) in clinical trials. [10]
• Treatment: Surgery (transoral robotic surgery) +/- radiotherapy +/- chemotherapy depending on stage.

---

9. Prevention

9.1 HPV Vaccination

UK HPV Vaccination Programme (2024)

Exam Detail: #### Vaccine Types

Vaccine Efficacy Data

• Cervical CIN 2/3 Prevention: 96-100% efficacy in vaccine-naive populations for vaccine types. [8]
• Genital Warts: 90% reduction in incidence in vaccinated cohorts (Australia, UK). [15]
• Cross-Protection: Some protection against non-vaccine high-risk types (e.g., HPV 31, 45) seen with bivalent/quadrivalent vaccines. Nonavalent vaccine includes these types directly.

Vaccination Post-Infection

• Vaccination after HPV infection provides no therapeutic benefit for existing infection.
• However, it prevents infection with other vaccine types not yet acquired.
• Vaccination recommended even after CIN treatment or genital warts.

Safety

• Highly safe. Common: Injection site pain, redness. Rare: Syncope (give seated, observe 15 minutes).
• No link to chronic fatigue, autoimmune conditions, or infertility (extensive post-marketing surveillance). [8]

9.2 Cervical Screening

• Secondary prevention: Detects CIN before progression to cancer.
• HPV primary screening (UK): More sensitive than cytology. Detects high-risk HPV DNA.
• Reduces cervical cancer incidence by ~60-80% and mortality by ~80% in screened populations. [9]

9.3 Barrier Methods

• Condoms: Reduce HPV transmission risk by ~50-70% but do not eliminate risk (exposed skin). [16]
• Dental dams: For oral-genital contact.

9.4 Other Preventive Measures

---

10. Complications and Sequelae

HPV-Related Cancers

Psychosocial Impact

• Anxiety and Distress: Diagnosis of HPV or genital warts causes significant distress (~30-50% report anxiety/depression). [15]
• Sexual Relationships: Concerns about transmission to partners. Disclosure difficulties.
• Stigma: Association with STIs. Misconceptions about fidelity and promiscuity.
• Management: Clear communication, reassurance (especially for low-risk types), psychological support, written information.

Obstetric Complications

• Vertical Transmission: Rare. Risk of juvenile-onset recurrent respiratory papillomatosis (JORRP) if HPV 6/11. [17]
• Caesarean Section: Not routinely indicated for genital warts or HPV. Only if warts obstruct birth canal.

Recurrent Respiratory Papillomatosis

• Juvenile-Onset: Acquired at birth. Recurrent laryngeal/tracheal papillomas. Requires repeated surgical debulking. Rarely undergoes malignant transformation.
• Cidofovir (off-label): Intralesional antiviral. May reduce recurrence rate.

---

11. Prognosis and Outcomes

Natural History of HPV Infection

CIN Regression and Progression

[Data from Östör AG, 1993 meta-analysis and subsequent studies] [7]

Treatment Outcomes

---

12. Special Populations

12.1 Immunocompromised Patients

HIV-Positive Patients

Exam Detail: HPV-HIV Co-Infection Implications:

Modified Screening Recommendations (HIV-Positive Women):

HIV Diagnosis
      ↓
Cervical Screening at Diagnosis
      ↓
  ┌───────────┴───────────┐
Abnormal            Normal
  ↓                    ↓
Colposcopy         Repeat 6 months
                        ↓
                   ┌────────┴────────┐
              Abnormal          Normal
                   ↓                ↓
              Colposcopy     Annual Screening
                              (lifelong)

• Annual cervical screening regardless of age (some guidelines recommend 6-monthly in first year after HIV diagnosis).
• Lower threshold for colposcopy referral.
• Consider anal cytology and high-resolution anoscopy in MSM and women with history of receptive anal intercourse.

Solid Organ Transplant Recipients

Other Immunosuppression

• Inflammatory Bowel Disease on immunosuppression: Increased CIN risk. Annual screening recommended by some guidelines.
• Systemic Lupus Erythematosus: Increased HPV persistence and CIN risk.
• Chemotherapy: Temporary immunosuppression. Resume screening post-treatment.

12.2 Pregnancy

HPV in Pregnancy

Management of Genital Warts in Pregnancy

Safe Treatments:

• Cryotherapy (first-line)
• Trichloroacetic Acid (TCA) 80-90%
• Surgical excision (if obstructing birth canal)

Contraindicated:

• Podophyllotoxin (teratogenic in animal studies)
• Imiquimod (insufficient safety data)
• Electrosurgery/Laser (theoretical viral aerosolisation risk)

Delivery Considerations:

• Vaginal delivery is safe in most cases.
• Caesarean section only if warts obstruct the birth canal (rare).
• Vertical transmission risk is less than 1%. Juvenile-onset recurrent respiratory papillomatosis (JORRP) is rare. [17]

Management of Abnormal Cervical Cytology in Pregnancy

Abnormal Cytology in Pregnancy
         ↓
   ┌────────────┴────────────┐
Low-Grade         High-Grade/Suspected Cancer
   ↓                       ↓
Defer Colposcopy      Colposcopy
to 12 weeks           (by experienced colposcopist)
postpartum                ↓
                    ┌───────────┴────────────┐
                CIN 1/2            CIN 3 or ?Cancer
                    ↓                       ↓
               Defer Treatment         Biopsy if indicated
               to Postpartum            (avoid ECC)
                                            ↓
                                   ┌────────┴────────┐
                                CIN 3          Invasive Cancer
                                   ↓                 ↓
                            Defer Treatment    MDT Discussion
                            to Postpartum      (Stage, Gestation,
                            (Monitor q trimester)  Maternal wishes)

• Low-grade cytology: Defer colposcopy to 12 weeks postpartum.
• High-grade cytology: Colposcopy in pregnancy to rule out invasive cancer. Avoid endocervical curettage (ECC).
• CIN 2/3: Conservative management. Repeat colposcopy each trimester. Treat postpartum (regression common postpartum). [20]
• Invasive cancer: MDT approach. Early-stage may allow delay until fetal maturity. Advanced-stage may require treatment during pregnancy.

12.3 Men Who Have Sex with Men (MSM)

Anal HPV and Cancer Risk

Anal Screening (Not Routine in UK)

• Anal cytology (anal Pap smear): Limited sensitivity (~70%).
• High-resolution anoscopy (HRA): Analogous to colposcopy. Gold standard for AIN diagnosis.
• HPV testing: High prevalence limits utility as screening test.

Current UK Position: Anal screening not part of routine care. Considered in specialist centres for high-risk groups (HIV-positive MSM, history of AIN/anal cancer).

Emerging Evidence: Studies underway to determine cost-effectiveness and optimal screening strategy.

HPV Vaccination in MSM

• UK programme: MSM up to age 45 eligible for Gardasil 9 via sexual health clinics.
• Rationale: High burden of anal cancer and genital warts. Vaccination offers protection even after HPV exposure (protection against vaccine types not yet acquired).
• Uptake: Lower than adolescent vaccination. Opportunistic offer during sexual health visits. [8]

12.4 Adolescents and Young Adults

Cervical Screening Considerations

• Do NOT screen less than 25 years (UK guidance). [9]
• Rationale:
  • High HPV prevalence but very low cancer incidence in this age group.
  • CIN 1/2 frequently regresses spontaneously in young women.
  • Overtreatment risk (LLETZ complications in future pregnancies).
  • Psychological harm from false positives.

HPV Vaccination Timing

• Optimal: Before sexual debut (age 12-13 in UK).
• Catch-up: Up to age 25. Still beneficial even if sexually active (protection against types not yet acquired).

12.5 Post-Hysterectomy

Vaginal Vault Screening

---

13. Public Health and Global Perspectives

13.1 Cervical Cancer as a Global Health Priority

Disease Burden Disparity

Key Drivers of Disparity:

• Lack of organised screening programmes in LMICs.
• Limited access to HPV vaccination.
• Poor access to treatment for pre-cancerous and cancerous lesions.
• Competing health priorities (HIV, malaria, tuberculosis).

13.2 WHO Cervical Cancer Elimination Strategy

Target: Eliminate cervical cancer as a public health problem by 2030.

90-70-90 Targets by 2030:

Projected Impact: If targets met, > 40% reduction in new cases and 5 million deaths averted by 2050. [14]

13.3 HPV Vaccination Global Coverage

High-Income Countries

• Australia: 80-90% coverage. First country on track to eliminate cervical cancer (projected less than 4 cases per 100,000 by 2035). [14]
• UK: ~85% coverage (single dose programme may improve uptake further).
• USA: ~55-60% coverage (lower than other HICs; vaccine hesitancy, access issues).

Low- and Middle-Income Countries

• Major Barrier: Vaccine cost (~$5-10 per dose via Gavi, but still prohibitive for some).
• Progress: Gavi-supported rollout in 50+ countries. Single-dose schedule reduces logistical barriers.
• Rwanda, Bhutan: Achieved > 90% coverage with national programmes.

13.4 Screening Strategies in Resource-Limited Settings

Screen-and-Treat Approaches

Traditional cytology-based screening is impractical in LMICs (requires laboratory infrastructure, multiple visits, high loss to follow-up).

Alternative Strategies:

WHO Recommendation: HPV testing preferred over VIA where feasible. Self-collection of samples increases screening uptake. [9]

13.5 Gender-Neutral Vaccination

Rationale

• Herd immunity: Vaccinating boys reduces HPV transmission to girls and women.
• Male cancers: Prevents oropharyngeal, anal, and penile cancers in men.
• MSM protection: MSM do not benefit from herd immunity if only girls vaccinated.
• Equity: Removes gender disparity in cancer prevention.

Global Adoption

• Gender-neutral vaccination: Implemented in Australia (2013), USA (2011), UK (2019), Canada, Austria, Italy, and others.
• Cost-Effectiveness: Marginal in countries with high female coverage but justified by male cancer prevention and equity.

13.6 Impact of Vaccination Programmes

Real-World Evidence

Key Message: HPV vaccination prevents cancer in real-world populations. First vaccine to achieve this.

13.7 Vaccine Hesitancy and Misinformation

Common Concerns (and Evidence-Based Responses)

Addressing Hesitancy:

• Healthcare provider recommendation is the strongest predictor of vaccine uptake.
• Emphasise cancer prevention (first anticancer vaccine).
• Use presumptive approach ("We'll do the HPV vaccine today") rather than participatory ("Do you want the HPV vaccine?").

---

14. Key Evidence and Guidelines

Guidelines

Landmark Evidence

---

13. Examination Focus

High-Yield Viva Questions and Model Answers

Q1: Which HPV types cause cervical cancer, and what is their relative contribution?

Model Answer: "High-risk HPV types, particularly HPV 16 and 18, are responsible for approximately 70% of cervical cancers globally. HPV 16 accounts for 50-55% and HPV 18 for 15-20%. The remaining 30% are caused by other high-risk types including HPV 31, 33, 45, 52, and 58. The nonavalent vaccine (Gardasil 9) covers HPV 16, 18, 31, 33, 45, 52, and 58, providing protection against ~90% of cervical cancers." [3,4,8]

Q2: Explain the molecular mechanism by which HPV causes cancer.

Model Answer: "High-risk HPV types encode E6 and E7 oncoproteins. E6 binds and degrades p53, a tumour suppressor that normally induces apoptosis in response to DNA damage. Loss of p53 leads to loss of apoptosis and genomic instability. E7 binds and inactivates the Retinoblastoma (Rb) protein, which normally inhibits E2F transcription factors and prevents cell cycle progression. E7-Rb binding releases E2F, causing uncontrolled cell cycle progression from G1 to S phase. In persistent infections, the viral genome may integrate into the host chromosome, disrupting the E2 gene that normally represses E6/E7 expression. This leads to constitutive overexpression of E6 and E7, driving malignant transformation over 10-20 years." [18,19]

Q3: Describe the UK cervical screening programme.

Model Answer: "The UK uses HPV primary screening. Women aged 25-49 are screened every 3 years, and women aged 50-64 every 5 years. The initial test is for high-risk HPV DNA. If HPV-negative, the woman returns to routine recall. If HPV-positive, reflex cytology is performed on the same sample. If cytology is normal, the woman is recalled for repeat HPV testing at 12 months. If HPV persists, she is referred for colposcopy. If cytology shows abnormalities (borderline, low-grade, or high-grade dyskaryosis), colposcopy is arranged. High-grade dyskaryosis or suspected invasive/glandular neoplasia triggers urgent colposcopy within 2 weeks." [9,20]

Q4: What is the difference between low-risk and high-risk HPV types? Give examples.

Model Answer: "Low-risk HPV types (e.g., HPV 6 and 11) cause genital warts and laryngeal papillomatosis but have no oncogenic potential. They account for ~90% of genital warts. High-risk HPV types (e.g., HPV 16, 18, 31, 33, 45, 52, 58) have oncogenic potential and cause cervical, anogenital, and oropharyngeal cancers. HPV 16 and 18 are responsible for ~70% of cervical cancers. The key difference is the presence of E6 and E7 oncoproteins in high-risk types that inactivate p53 and Rb, leading to uncontrolled cell proliferation and malignant transformation." [3,5,18]

Q5: A 28-year-old woman has an HPV-positive cervical screening test with normal cytology. What is your management?

Model Answer: "I would explain that the test shows high-risk HPV infection but no abnormal cells at present. The appropriate management is repeat HPV testing at 12 months, as many HPV infections clear spontaneously within this timeframe. If HPV clears (negative at 12 months), she returns to routine recall (3-yearly). If HPV persists (positive at 12 months), she should be referred for colposcopy to directly visualise the cervix and perform biopsies if indicated. I would reassure her that most HPV infections clear naturally and that we are monitoring to ensure early detection if any pre-cancerous changes develop." [9,20]

Q6: What are the components of the Gardasil 9 vaccine, and who should receive it?

Model Answer: "Gardasil 9 is a nonavalent HPV vaccine protecting against 9 HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. It prevents ~90% of cervical cancers and ~90% of genital warts. In the UK, it is offered to all children aged 12-13 years (Year 8) as a single dose (schedule changed in 2023 based on WHO guidance). Catch-up vaccination is available for those who missed it, up to age 25. Men who have sex with men (MSM) are eligible up to age 45 via sexual health clinics due to higher anal cancer risk. The vaccine is most effective when given before sexual debut (vaccine-naive), but provides benefit even after HPV exposure by protecting against other vaccine types." [8]

Q7: What are the treatment options for genital warts?

Model Answer: "Treatment options include patient-applied and clinician-applied therapies. Patient-applied options are Podophyllotoxin 0.5% (antimitotic agent; applied twice daily for 3 days, then 4 days off, for up to 4 cycles) and Imiquimod 5% (immune response modifier; applied 3 times weekly at night for up to 16 weeks). Clinician-applied options include Cryotherapy (liquid nitrogen; first-line in the UK, repeated every 1-2 weeks for up to 6 cycles), Electrosurgery (for larger or refractory warts), Surgical Excision (for large pedunculated warts), Trichloroacetic Acid (chemical cautery), and Laser Ablation (for extensive or refractory cases). Recurrence occurs in ~30% of cases. I would also offer a full STI screen and partner notification. In pregnancy, safe options include Cryotherapy, TCA, and Surgical Excision (avoid Podophyllotoxin and Imiquimod)." [15]

Q8: Why is HPV-positive oropharyngeal cancer considered to have a better prognosis?

Model Answer: "HPV-positive oropharyngeal cancers (predominantly HPV 16) have a significantly better prognosis than HPV-negative (tobacco/alcohol-related) cancers, with 5-year survival rates of ~80% vs ~50%. The reasons include: patients with HPV-positive tumours tend to be younger with fewer comorbidities, the tumours are more radiosensitive and chemosensitive, and they present at earlier T-stage (though often with lymph node involvement, which paradoxically has a better prognosis in HPV-positive disease). This has led to interest in de-escalation therapy (lower radiation doses) in clinical trials to reduce long-term toxicity while maintaining cure rates." [10]

Q9: How does HIV infection affect HPV-related disease?

Model Answer: "HIV infection significantly impacts HPV-related disease due to impaired cell-mediated immunity. HIV-positive individuals experience higher HPV persistence rates, faster progression from CIN to invasive cervical cancer, and a 5-6 fold increased risk of cervical cancer. They also have higher rates of anal cancer (particularly in men who have sex with men), vulvar and vaginal cancers, and genital warts. Management includes more frequent cervical screening (annually in some guidelines), consideration of anal cytology and high-resolution anoscopy in high-risk groups, optimisation of HIV control with antiretroviral therapy, and HPV vaccination (though efficacy may be reduced in severely immunosuppressed individuals). Cervical cancer is an AIDS-defining illness in HIV-positive women." [11]

Q10: What is LLETZ, and when is it indicated?

Model Answer: "LLETZ (Large Loop Excision of the Transformation Zone) is a diagnostic and therapeutic procedure for high-grade cervical dysplasia. A wire loop heated by electrical current is used to excise the transformation zone of the cervix under local anaesthesia during colposcopy. It is the first-line treatment for CIN 2 and CIN 3. LLETZ has the advantage of providing tissue for histological assessment (confirming grade and excision margins) and can be performed as a "see-and-treat" procedure (same visit as colposcopy) if indicated. Post-treatment follow-up includes a Test of Cure (HPV test at 6 months). Complications include bleeding (~5%), infection (~2-3%), cervical stenosis (less than 1%), and obstetric complications (increased risk of preterm birth and premature rupture of membranes in future pregnancies)." [20]

Q11: A 35-year-old HIV-positive woman asks about cervical screening. What do you advise?

Model Answer: "I would explain that HIV increases the risk of cervical cancer by 5-6 fold due to impaired immune clearance of HPV. Therefore, more frequent screening is recommended. She should have annual cervical screening (some guidelines recommend 6-monthly in the first year after HIV diagnosis). If any abnormality is detected, the threshold for colposcopy is lower than in HIV-negative women. Additionally, if she has a history of receptive anal intercourse, we may discuss anal cytology and screening for anal dysplasia, given the high anal cancer risk in HIV-positive individuals. Optimising her HIV control with antiretroviral therapy is also crucial for reducing HPV persistence and cancer risk. HPV vaccination is recommended, though efficacy is best when CD4 count is > 200." [11]

Q12: What is the Test of Cure, and why is it important after CIN treatment?

Model Answer: "The Test of Cure (ToC) is an HPV test performed at 6 months post-treatment (e.g., after LLETZ for CIN 2/3). It is more sensitive than cytology for detecting residual or recurrent disease. If the HPV test is negative, the risk of recurrence is very low (less than 5%), and the woman can return to routine recall (though often with enhanced surveillance for 10 years—annual or 3-yearly depending on protocol). If the HPV test is positive, this indicates persistent infection and higher risk of recurrence or residual disease, warranting colposcopy for further assessment. The ToC is critical because incomplete excision or new HPV infection can lead to recurrent CIN or progression to cancer if not detected early." [20]

Q13: Explain the difference between cervical screening and HPV testing.

Model Answer: "Cervical screening is a population-based programme to detect pre-cancerous changes (CIN) before they progress to cervical cancer. In the UK, this uses HPV primary testing: the initial test detects high-risk HPV DNA (not all HPV, just the 14 oncogenic types). If HPV is negative, no further testing is needed (routine recall). If HPV is positive, cytology is performed on the same sample to look for abnormal cells. HPV testing identifies those at risk, and cytology triage determines who needs colposcopy. This is more sensitive than cytology alone and allows earlier detection of high-risk individuals. Screening is offered to women aged 25-64 years (not younger, due to high HPV prevalence and low cancer risk). The goal is to detect CIN 2/3, not merely HPV infection, which is very common and usually transient." [9,20]

Q14: What counselling would you provide to a patient diagnosed with genital warts?

Model Answer: "I would explain that genital warts are caused by low-risk HPV types 6 and 11, which do not cause cancer—this is very important for reassurance. Warts are very common and spread by skin-to-skin contact, so condoms reduce but do not eliminate transmission. Treatment options include self-applied creams (podophyllotoxin, imiquimod) or clinic-based treatments (cryotherapy, excision). Warts may recur (~30%) and may need repeated treatment, but they usually resolve over time (months to years). I would recommend a full sexual health screen to check for other STIs. Current sexual partners should be informed, though it's often impossible to determine when or from whom HPV was acquired. Warts do not affect fertility or pregnancy, though they may proliferate during pregnancy. I would address any psychosexual concerns and provide written information and support resources." [5,15]

Q15: Why is oropharyngeal cancer due to HPV rising, and what are the implications?

Model Answer: "HPV-positive oropharyngeal cancer, predominantly caused by HPV 16, has shown rising incidence over the past 2-3 decades, particularly in men in high-income countries. This is attributed to changing sexual behaviours (increased oral-genital contact) over generations. In some countries, HPV-positive oropharyngeal cancer now exceeds cervical cancer incidence. The implications are significant: HPV-positive tumours have a better prognosis than HPV-negative (tobacco/alcohol-related) cancers (5-year survival ~80% vs ~50%), which has led to interest in de-escalation therapy to reduce treatment toxicity. HPV vaccination (especially with Gardasil 9) is expected to reduce oropharyngeal cancer incidence in future decades. However, there is currently no screening programme for oropharyngeal cancer, and most cases present symptomatically (neck mass, sore throat, dysphagia)." [10]

Common OSCE/Clinical Scenarios

Scenario 1: Explaining HPV Diagnosis to a Patient with Genital Warts

Key Points:

• Genital warts are caused by HPV 6 and 11 (low-risk types).
• Very common. Most sexually active people get HPV at some point.
• Not cancer-causing. Different types from those that cause cervical cancer.
• Spread by skin-to-skin contact. Condoms reduce but do not eliminate risk.
• Treatment options available (creams, freezing). May need repeated treatment.
• Warts often resolve over time (months to years).
• Partner should be examined if symptomatic.
• Full STI screen recommended.
• No impact on fertility or pregnancy (usually).

Scenario 2: Counselling a Parent About HPV Vaccination

Key Points:

• Prevents cancer. First vaccine to do so.
• Protects against 9 HPV types (Gardasil 9).
• Prevents ~90% of cervical cancers and ~90% of genital warts.
• Safe. Extensively tested. Mild side effects (sore arm).
• Single dose at age 12-13 (Year 8).
• Most effective before sexual activity starts.
• Does not protect against all HPV types. Cervical screening still important in adulthood.
• Routine in UK since 2008 (girls) and 2019 (all children).

Scenario 3: Managing Abnormal Cervical Screening Result

Task: Explain HPV-positive, normal cytology result to a 32-year-old woman.

Key Points:

• HPV detected but no abnormal cells currently.
• HPV is very common. Most people clear it naturally within 1-2 years.
• Repeat test in 12 months to see if HPV clears.
• If HPV clears → routine screening (3-yearly).
• If HPV persists → colposcopy (closer look at cervix).
• This is early detection working—we're monitoring before any problem develops.
• No treatment needed now (HPV has no cure, but body usually clears it).
• Continue routine activities (work, sex, exercise).
• Cervical screening still needed even if vaccinated (vaccine doesn't cover all types).

Scenario 4: Discussing CIN 2 Diagnosis and LLETZ

Task: Counsel a 29-year-old woman with CIN 2 on colposcopy biopsy.

Key Points:

• CIN 2 = moderate abnormal cells (pre-cancerous, not cancer).
• Caused by persistent HPV infection.
• Without treatment, ~20% progress to CIN 3 and ~5% to cancer over many years.
• Treatment: LLETZ (Loop Excision). Removes abnormal area. Done under local anaesthetic at colposcopy.
• Quick procedure (~10-15 minutes). Can usually go home same day.
• Test of Cure at 6 months (HPV test). If negative, very low risk of recurrence.
• Potential complications: Bleeding (~5%), infection (~2%), preterm birth risk in future pregnancies (slight increase—discuss with obstetrician if planning pregnancy).
• Curable condition. Treatment is very effective (~95% cure rate).

Scenario 5: Explaining Cervical Screening to a 24-Year-Old

Task: A 24-year-old requests cervical screening. Explain why she is not eligible.

Key Points:

• Screening starts at age 25 in the UK.
• Rationale: Cervical cancer is extremely rare in women less than 25 (even if HPV-positive).
• HPV is very common in women in their early 20s (30-40% prevalence) but usually clears spontaneously.
• Screening less than 25 would lead to overtreatment of abnormalities that would regress naturally.
• Treatment (LLETZ) has risks (preterm birth in future pregnancies).
• Psychological harm from false positives.
• First screen at age 25 (invitation letter sent automatically).
• If symptoms (post-coital bleeding, abnormal discharge) → see GP for examination (not screening).
• HPV vaccination is recommended if not already vaccinated (up to age 25).

---

15. Patient and Layperson Explanation

What is HPV?

HPV stands for Human Papillomavirus. It's a very common virus that affects the skin and moist membranes of the body. There are over 200 different types of HPV. Most people will get HPV at some point in their lives, usually through sexual contact.

How common is HPV?

HPV is the most common sexually transmitted infection. About 8 out of 10 people will get it at some point. Most people don't even know they have it because it usually doesn't cause any symptoms and goes away on its own.

How do you get HPV?

HPV spreads through skin-to-skin contact, usually during sexual activity (vaginal, anal, or oral sex). You can get HPV the first time you have sexual contact. Condoms help reduce the risk but don't completely prevent HPV because they don't cover all the skin.

What can HPV cause?

• Most HPV infections cause nothing. Your body's immune system clears the virus naturally within 1-2 years.
• Low-risk types (HPV 6 and 11): Cause genital warts. These are harmless growths that can be treated but are not dangerous.
• High-risk types (HPV 16 and 18): Can cause cervical cancer, and other cancers (mouth, throat, anus, penis, vulva, vagina). This happens very rarely and usually only if the infection persists for many years.

How can I protect myself?

1. HPV Vaccine: The best protection. Given to children aged 12-13 in school. It prevents the types of HPV that cause most cancers and genital warts. Safe and very effective.
2. Cervical Screening (Smear Test): For women aged 25-64. Detects early changes in the cervix before cancer develops. Saves lives.
3. Condoms: Reduce the risk of HPV and other STIs, but don't fully protect against HPV.

What if I have genital warts?

• Genital warts are caused by low-risk HPV (types 6 and 11).
• They are not dangerous and do not cause cancer.
• Treatments available: Creams you apply at home or treatment at a clinic (freezing, laser).
• Warts may come back and need more treatment, but they usually go away over time.
• You should get a full sexual health check to make sure you don't have other infections.

What if my smear test is HPV-positive?

• This means you have a high-risk type of HPV (one that can cause cervical cancer).
• It's very common. Most people clear the virus naturally.
• If you have HPV but normal cells, you'll be asked to come back in 12 months for another test.
• If the HPV is still there, you'll be referred to a specialist clinic (colposcopy) for a closer look at your cervix.
• Early detection prevents cancer. This is why screening is so important.

Can HPV be cured?

There is no cure for the virus itself, but your body usually clears it naturally within 1-2 years. Treatments are available for the problems HPV causes (warts, abnormal cervical cells, cancer), but not the virus itself.

Should I tell my partner?

If you have genital warts or cervical cell changes, it's a good idea to let your current partner(s) know. They may want to get checked. HPV is so common that it's often impossible to know when or from whom you got it. It doesn't mean anyone has been unfaithful.

---

15. References

Primary Sources

1. de Sanjosé S, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-56. PMID: 20952254. DOI: 10.1016/S1470-2045(10)70230-8.

2. Doorbar J, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30 Suppl 5:F55-70. PMID: 23199966. DOI: 10.1016/j.vaccine.2012.06.083.

3. Schiffman M, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907. PMID: 17826171. DOI: 10.1016/S0140-6736(07)61416-0.

4. Bouvard V, et al. A review of human carcinogens—Part B: biological agents. Lancet Oncol. 2009;10(4):321-2. PMID: 19350698. DOI: 10.1016/S1470-2045(09)70096-8.

5. Lacey CJN, et al. 2012 European guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol. 2013;27(3):e263-70. PMID: 22409368. DOI: 10.1111/j.1468-3083.2012.04493.x.

6. Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev. 2012;25(2):215-22. PMID: 22491772. DOI: 10.1128/CMR.05028-11.

7. Östör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12(2):186-92. PMID: 8463044.

8. Falcaro M, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398(10316):2084-92. PMID: 34741816. DOI: 10.1016/S0140-6736(21)02178-4.

9. Ogilvie GS, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA. 2018;320(1):43-52. PMID: 29971397. DOI: 10.1001/jama.2018.7464.

10. Chaturvedi AK, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294-301. PMID: 21969503. DOI: 10.1200/JCO.2011.36.4596.

11. Denny LA, et al. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine. 2012;30 Suppl 5:F168-74. PMID: 23199960. DOI: 10.1016/j.vaccine.2012.06.045.

12. Bruni L, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report 2023. [Accessed 2025].

13. Franceschi S, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer. 2006;119(11):2677-84. PMID: 16991121. DOI: 10.1002/ijc.22241.

14. Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. PMID: 33538338. DOI: 10.3322/caac.21660.

15. British Association for Sexual Health and HIV (BASHH). UK National Guideline on the Management of Anogenital Warts. 2015 (Updated 2021). Available at: www.bashh.org/guidelines.

16. Appleby P, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370(9599):1609-21. PMID: 17993361. DOI: 10.1016/S0140-6736(07)61684-5.

17. Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope. 2008;118(7):1236-47. PMID: 18496162. DOI: 10.1097/MLG.0b013e31816a7135.

18. Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol. 2009;19(2):97-113. PMID: 19156753. DOI: 10.1002/rmv.605.

19. Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol. 2007;212(4):356-67. PMID: 17573670. DOI: 10.1002/path.2192.

20. NHS Cervical Screening Programme. Colposcopy and Programme Management (NHSCSP Publication No 20). 3rd Edition. 2016. Available at: www.gov.uk/government/publications/cervical-screening-programme-and-colposcopy-management.

21. Joura EA, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-23. PMID: 25693011. DOI: 10.1056/NEJMoa1405044.

22. Giuliano AR, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet. 2011;377(9769):932-40. PMID: 21367446. DOI: 10.1016/S0140-6736(10)62342-2.

23. Petrosky E, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300-4. PMID: 25811679.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines.